| abstract |
Useful in the treatment of diseases associated with modulation of glucocorticoid receptor, AP-1, and / or NF-κB activity, such as metabolic and inflammatory or immune related diseases or disorders, Formula I: (I) [Where: A is a 5, 6 or 7 membered heterocyclo or heteroaryl, each containing 1, 2 or 3 heteroatoms selected from N, O and S, and 1-4 R 1 , Substituted with R 2 , R 3 , and / or R 4 groups; M is selected from alkyl, cycloalkyl, aryl, heterocyclo, and heteroaryl; Z is alkyl, CF 3 , OH, cycloalkyl, heterocyclo, aryl, heteroaryl, —C (═O) NR 8 R 9 , —C (═O) R 8 , —C (NCN) NR 8 R 9 , Selected from —C (═O) OR 8 , —SO 2 R 8 , and —SO 2 NR 8 R 9 ] A novel non-steroidal compound having the structure: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt thereof is provided. Also provided are pharmaceutical compositions, combination medicaments, and methods of treating metabolic and inflammatory or immune related diseases or disorders using the compounds described above. |